FDA responds positively to IOM report

Share this article:
FDA commissioner Andrew von Eschenbach on Jan. 30 unveiled a comprehensive series of steps now being undertaken in direct response to last September's Institute of Medicine report that sharply criticized the FDA's drug safety program and that recommended changes to the nation's drug safety system.

“We find we are in substantial agreement with most of the IOM recommendations,” von Eschenbach said. “The initiatives we are announcing today are not just a plan, but a real pathway to enhanced drug safety.”

The IOM report, requested by the FDA in 2005 in the wake of  safety problems with Vioxx and other medications, was delivered to the agency last September.

Von Eschenbach said a “transformation” of FDA's drug safety system will be accomplished by undertaking changes in three critical areas: by strengthening the science that supports the medical product safety system; by improving communication and information flow among health care providers and consumers; and by making certain improvements to internal agency operations and management.

Specific activities include development of new scientific approaches to detecting, predicting and preventing adverse events and new quantitative tools to assess benefits and risks associated with drug use; formation of a new advisory committee to recommend improvements to the agency's risk communication policies and practices; and development of a new pilot program to assess the utility of postmarketing evaluations for routine new molecular entities.  

Share this article:
close

Next Article in News

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.